Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

Shimadzu Corporation. (7/26/11). "Press Release: National Cancer Center (NCC) and Shimadzu Corporation Reach Comprehensive Collaborative Research Agreement".

Region Region Japan
Organisations Organisation Shimadzu Corporation
  Group Shimadzu (Group)
  Organisation 2 National Cancer Center (NCC) (JP)
Products Product mass spectrometry (MS)
  Product 2 oncology
Index term Index term National Cancer Center (JP)–Shimadzu: mass spectrometry, 201106– collab long-term intergration of MS + chromatography with other cancer research techn
Persons Person Kayama, Takamasa (National Cancer Center (JP) 201106 Chief Director)
  Person 2 Nakamoto, Akira (Shimadzu 201504– Board Chairma before CEO)
     


On June 15th 2011, the National Cancer Center (Chief Director: Takamasa Kayama, M.D., Ph.D.; situated in Chuo-ku, Tokyo; referred to herein as the NCC), an independent administrative institution (IAI), reached a comprehensive collaborative research agreement with Shimadzu Corporation (President: Akira Nakamoto; situated in Nakagyo-ku, Kyoto; referred to herein as Shimadzu).

The purpose of this agreement is to develop internationally leading, high-level, cutting-edge medical technologies that contribute to the suppression of cancer and the promotion of human health. These include technological developments related to the realization of ultra-early cancer diagnoses, pharmacokinetic analysis for the achievement of a revolution in the drug discovery process, and medical treatments. These developments will be accomplished through a fusion of the high-level cancer research techniques and clinical experience at the NCC with Shimadzu's cutting-edge technologies in next-generation medical treatment fields.

The primary collaborative and cooperative activities stipulated in this agreement consist of (1) cooperative research and other research collaborations; (2) exchanges of research techniques, research materials, and other research information; (3) exchanges of researchers and technical staff; (4) cultivation of the next generation of researchers and technicians; and (5) promotion of the reciprocal use of the facilities, equipment, and instruments owned by the respective parties.

Established in 1962, the NCC is the leading Japanese medical institution for cancer treatment and research, and has a wealth of experience in terms of clinical studies. In discussing his hopes for collaborative research, Chief Director Kayama of the NCC stated that he would like to see "the union with Shimadzu lead to the development of equipment that can be used throughout the world, so as to effect and advance the change from life science to medical science."

Shimadzu is pursuing research and development in the next-generation medical treatment fields of molecular imaging technology and biomarker searches, based on the fusion and application of its chromatography, mass spectrometry and other core analysis and measuring technology with medical imaging technology. In indicating his ambitions, Shimadzu's President Nakamoto noted that "thus far, the life sciences have been the core enterprise at Shimadzu. In the future, however, I would like to see the biomarker candidates discovered to date applied to ultra-early diagnosis; we believe this can be accomplished through the implementation of clinically useful medical science and a fusion of imaging diagnostics and molecular imaging, in conjunction with the NCC."

To date, the NCC and Shimadzu have pursued collaborative research based on individual themes, including examinations of the clinical applications of the "tomosynthesis" cutting-edge medical imaging technology. By establishing an even closer bond between the parties, leading to the development of revolutionary, next-generation medical treatment systems, this agreement is likely to contribute to reducing the number of people who die from cancer while improving the quality of medical treatment available for cancer patients.

   
Record changed: 2019-06-09

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 650x99px

More documents for Shimadzu (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top